文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

前列腺癌5次、2次或1次MR引导超低分次放疗的可行性

Feasibility of MR-guided ultrahypofractionated radiotherapy in 5, 2 or 1 fractions for prostate cancer.
PubMed 文献 · Clin Transl Radiat Oncol · 2020-10-27

5次分次方案全部计划满足所有临床目标,2次和1次分次方案各有6例满足。研究提示超低分次治疗计划可行,但需结合实时运动缓解策略。

要点

  • 2次和1次分次方案各有6例满足所有临床目标。
  • 2次和1次分次方案PTV D95%分别最多降低6.4%和3.9%的靶区剂量。

核心结论

  • 结合实时运动缓解策略时,前列腺癌超低分次MR引导放疗计划方法具有可行性。

主要发现

  • 2次和1次分次方案各有6例计划满足所有临床目标。
  • 2次和1次分次方案PTV D95%分别最多降低6.4%和3.9%的相应靶区剂量。
  • 2次分次方案中有2例PTV D95%降低超过5%剂量。

关键数值与推荐

  • 靶区处方和计划约束来源于HDR近距离治疗与SBRT文献。
  • 2次和1次分次方案各6例满足所有临床目标,PTV D95%最多降低6.4%和3.9%。

临床怎么用

  • 超低分次MR引导前列腺放疗计划需结合实时运动缓解策略以保证靶区覆盖。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The drive towards hypofractionated prostate radiotherapy is motivated by a low alpha/beta ratio for prostate cancer (1 to 3 Gy) compared to surrounding organs at risk, implying an improved therapeutic ratio with increasing dose per fraction. Early evidence from studies of ultrahypofractionated (UHF) prostate HDR brachytherapy has shown good tolerability in terms of normal tissue toxicities and clinical outcomes similar to conventional fractionation schedules. MR-guided stereotactic body radiotherapy (SBRT) with online plan adaptation and real-time tumour imaging may enable UHF doses to be delivered to the prostate safely, without the invasiveness of brachytherapy. The feasibility of UHF prostate treatment planning for the Unity MR-Linac (MRL, Elekta AB, Stockholm) was investigated for target prescriptions and planning constraints derived from the HDR brachytherapy and SBRT literature. Monaco 5.40 (Elekta) was used to generate MRL step-and-shoot IMRT plans for three dose fractionation protocols (5, 2 and 1 fractions), for ten randomly selected previously treated prostate cancer patients. Of the ten plans per UHF scheme, all clinical goals were met in all cases for 5 fractions, and in six cases for both 2 and 1 fraction schemes. PTV D95% was compromised by up to 6.4% and 3.9% of the associated target dose for 2 and 1 fraction plans respectively. There were two cases of PTV D95% compromise greater than a 5% dose decrease for the 2 fraction plans. The study suggests feasibility of the UHF treatment planning approaches if combined with real-time motion mitigation strategies.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Mohajer J, Dunlop A, Mitchell A, et al. Feasibility of MR-guided ultrahypofractionated radiotherapy in 5, 2 or 1 fractions for prostate cancer. Clin Transl Radiat Oncol. 2020. PMID: 33241129. doi:10.1016/j.ctro.2020.10.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。